California Approves $8.4 Billion Medical Research Bond

On November 9, California voters approved Proposition 38, authorizing the state to borrow $8.4 billion for immunology and immunotherapy research intended to prevent and treat chronic diseases. At least $4.2 billion must support research into cancer, heart disease and Alzheimer’s disease.

The bond money is to be divided evenly between one institute chosen by California’s public health agency and competitive research grants. The institute must be affiliated with the University of California. Grants will be awarded by a council representing UC campuses, universities and nonprofit research institutions.

Opponents say the measure’s eligibility rules mean only one California institute currently qualifies for half the bond allocation: the California Institute for Immunology and Immunotherapy, co-founded by Gary K. Michelson. Michelson, a retired surgeon and medical-device inventor, was the proposition’s largest backer, contributing more than $40 million to its campaign.

The state Legislative Analyst’s Office estimates bond repayment will cost taxpayers $500 million to $600 million a year for about 20 years. Proposition 38 directs 10% of revenue generated by funded research to the state General Fund until borrowing costs, including interest, are repaid. Any additional revenue would support future research, though the amount and timing of any returns are uncertain.

Supporters, including the Alzheimer’s Association, the Michael J. Fox Foundation for Parkinson’s Research and City of Hope, argue the measure could sustain research and help produce treatments. They also point to cuts in federal medical-research funding. Opponents question the concentration of funding in one institute and the limits on research fields.

Voters Back New Funding for California Medical Research

California voters have approved Proposition 38, committing $8.4 billion in state borrowing to immunology and immunotherapy research. The vote backs a major new source of support for work on cancer, heart disease and Alzheimer’s disease as the Trump administration cuts billions in medical-research funding at universities and medical centers.

The measure divides the money evenly between a University of California-affiliated nonprofit institute and competitive grants. Supporters, including the Alzheimer’s Association, the Michael J. Fox Foundation for Parkinson’s Research and City of Hope, say the investment could help prevent disease and deliver life-saving treatments. Zev Yaroslavsky of UCLA’s Luskin School of Public Affairs argued that failing to pass the measure would gut research momentum.

That promise comes with a cost: California is expected to pay $500 million to $600 million annually for about 20 years to repay the bonds. Proposition 38 requires 10% of revenue from funded discoveries to go to the state until the borrowed amount and interest are repaid, but the timing and scale of any returns are uncertain.

The measure also directs half the funding to one institute selected by the state. Critics say its specific eligibility rules currently leave only the California Institute for Immunology and Immunotherapy qualified. That concern deserves scrutiny, but it does not erase the stakes supporters see in preserving research capacity and pursuing treatments for serious diseases.

California Taxpayers Take On $8.4 Billion Research Debt

California voters have approved Proposition 38, authorizing $8.4 billion in state bonds for immunology research. The measure puts taxpayers on the hook for an estimated $500 million to $600 million a year for roughly 20 years, while the prospect of revenue from future discoveries remains uncertain.

Half the funding is directed to a single institute selected by the state, and opponents say the narrow eligibility rules currently leave just one California institution qualified: the California Institute for Immunology and Immunotherapy. Gary K. Michelson, who co-founded the institute, was also the measure’s largest campaign backer, contributing more than $40 million.

The rest of the bond proceeds will support competitive grants, but the measure limits the research focus to immunology and immunotherapy. Robert Kaplan, a co-chair of the opposition campaign, has argued that research should be open to competition among institutions and cover a wider range of biomedical fields.

Supporters say the investment could lead to treatments for cancer, heart disease and Alzheimer’s disease, and that a share of research revenue will eventually reimburse the state. But Proposition 38’s repayment plan depends on discoveries producing income, and even supporters’ goal of sustaining research does not settle who receives the money or when taxpayers will see returns.